Treatment Information

Back

Liver Cancer treatment details. Biologic therapy.

National Cancer Center, Goyang, Gyeonggi, Korea.

Survival: monthsCountry:Korea
Toxiciy Grade:4City/State/Province:Goyang, Gyeonggi
Treatments:Biologic therapyHospital:National Cancer Center
Drugs:Journal:Link
Date:Mar 2011

Description:

Patients:
This study consisted of 55 patients with advanced hepatocellular carcinoma. The median patient age was 60 years (range of 27-80) and 89.1% were male.

Treatment:
Patients were treated with the biologic therapy agent brivanib, which inhibits proteins (FGF and VEGF) involved in cancer cell growth.

Toxicities:
The maximum reported toxicity level was grade 4, including fatigue (grade 3-4 in 16.4% of patients), hypertension (10.9% with grade 3-4), and diarrhea (3.6% with grade 3-4).

Results:
The median progression-free survival for this study was 2.7 months. The median overall survival was 10 months.

Support:
This study was supported by Bristol Myers-Squibb, the makers of brivanib.

Correspondence: Dr. Joong-Won Park; email: [email protected]



Back